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A i m.  The aim of the study was comparison of the results of sequential and concurrent chemoradiotherapy in patients
with advanced inoperable NSCLC.
M a t e r i a l  a n d  m e t h o d s.  Between 2001-2004 in the group of 173 patients with locally advanced, inoperable NSCLC the
randomized, prospective clinical trial was conducted. The study group consisted of 2 arms: in 89 patients neoadjuvant
chemotherapy plus teleradiotherapy was used; in 84 patients concurrent chemo- radiotherapy was given. In both groups
conformal radiotherapy and 2-drug chemotherapy cisplatin and navelbine was given. The only difference between the two
groups was the sequency of radiotherapy and chemotherapy.
R e s u l t s.  The similar benefit of both methods adding chemotherapy to radiation therapy was established. 2-year
overall survival and disease free survival in sequential therapy arm was 25.8% and 11.2% and in concurrent therapy group
25.0% and 11.9% respectively. The rate of toxicity of treatment in concurrent therapy arm was statistically significantly
higher; full treatment according to the plan was given to 96.7% patients treated sequentialy and to 75% in concurrently treated
group.
Conclusion.  The results of sequential and concurrent chemo- radiotherapy in locally advanced inoperable NSCLC are very
much the same but the toxicity due to treatment was significantly higher in the latter group.
Ocena skutecznoÊci skojarzonej chemio- teleradioterapii chorych na miejscowo zaawansowanego,
nieoperacyjnego, niedrobnokomórkowego raka p∏uca
(kontrolowane doÊwiadczenie kliniczne)
C e l  p r a c y.  Celem badaƒ by∏o porównanie skutecznoÊci sekwencyjnego i równoczesnego kojarzenia chemio- i teleradioterapii
chorych na miejscowo zaawansowanego, nieoperacyjnego, niedrobnokomórkowego raka p∏uca.
M a t e r i a ∏  i m e t o d y.  W grupie 173 chorych na miejscowo zaawansowanego, nieoperacyjnego, niedrobnokomórkowego
raka p∏uca przeprowadzono, w latach 2001-2004, prospektywne, kontrolowane doÊwiadczenie kliniczne. DoÊwiadczenie
mia∏o dwa ramiona: u 89 chorych zastosowano indukcyjnà chemioterapi´ z nast´powà teleradioterapià, u 84 chorych
równoczesnà chemio- teleradioterapi´. W obu grupach chorych stosowano teleradioterapi´ konformalnà oraz chemioterapi´
dwulekowà (cisplatyna + nawelbina). Ró˝nica obu schematów leczenia polega∏a wy∏àcznie na sekwencji stosowania chemio-
i teleradioterapii.
W y n i k i.  Stwierdzono podobnà skutecznoÊç obu metod kojarzenia chemio- i teleradioterapii. 2-letnie prze˝ycia ca∏kowite
i bezobjawowe, w grupie chorych leczonych sekwencyjnie, wynios∏y odpowiednio 25,8% i 11,2%, w grupie leczonej
równoczeÊnie – 25,0% i 11,9%. ToksycznoÊç leczenia równoczesnego by∏a znamiennie statystycznie wy˝sza; z tego
powodu pe∏ne zaplanowane leczenie przeprowadzono u 96,7% chorych leczonych sekwencyjnie, a tylko u 75% leczonych
równoczeÊnie.
1 Department of Radiotherapy I
2 Department of Radiotherapy II
3 Department of Gynaecological Oncology
4 Department of Surgical Oncology
Maria Sk∏odowska-Curie Memorial Cancer Center
and Institute of Oncology, Cracow Branch, Poland
Grant KBN 6 P05B 001 20
The mainstay of treatment of locoregionally advanced
[III°] nonresactable, Non-Small Cell Lung Cancer
(NSCLC)is irradiation. The results of radiotherapy as
a sole modality are nevertheless poor, especially in
patients in grade IIIA (with the N2 feature) and IIIB
(T4 and/or N3). Only a few percent of patients achieve
a 5-year survival, while mean survival time ranges between
a few months and two years [1-12]. A number of attempts
have been made to alter this situation – these include
increasing the total irradiation dose, using unconventional
methods of fractioning (CHART, HART), administering
radio-sensitising substances, 3D treatment planning,
combining teletherapy and brachytherapy [1, 2, 5, 7, 8,
13-16]. However, over the last few years the most
promising method appears to be the administration of
conformal radiotherapy with intensity modulated radio-
therapy (IMRT) [1, 5, 6, 8, 10].
Another promising modality is combined radio-
chemotherapy. Theoretically, this method allows to
increase the chances of local cure and to limit the
frequency of distant metastases, which are usually the
only or the main reason for treatment failure in some
75% of patients with NSCLC [1, 3, 5, 7, 8, 10, 17]. The
results of controlled clinical trials and metaanalyses, which
have been hitherto published stress the increased efficacy
of combined treatment (radio- and chemotherapy) as
compared to radiotherapy alone, although the impro-
vement in long term survival does not exceed a few
percent [1, 2, 7, 8, 10, 17-21]. A number of issues remain
to be resolved, such as patient qualification for combined
therapy, treatment toxicity, its impact on the quality of
life, optimal radio- and chemotherapy treatment protocols
and the economical aspects.
Some controversies are also evoked regarding the
optimal sequence in which radio- and chemotherapy
should be combined. Both these methods may be
administered sequentially (in which case chemotherapy is
usually administered as the first modality) or concurrently.
Literature data suggests that induction chemotherapy,
followed by radiotherapy is less toxic, but also less
efficient than concurrent chemo- and radiotherapy [7, 8,
22-24]. The aim of this paper is to verify hypotheses
derived from published data basing upon an analysis of
the results of a randomized prospective trail performed at
the Kraków branch of the Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology
(COOK).
Material and methods
The prospective randomized trial was set according to the
outlines presented by Bryse, Stagnet and Sylwester in their
publication “Cancer Clinical Trials; Methods and Practice”
(Oxford Medical Publ. 1992). We obtained the opinion of the
Local Ethics Committee of the COOK. On entering the trial
the patients were provided with all the information concerning
its objectives and regulations and they all consciously gave signed
consent. The study group was dichotomized into patients
receiving induction chemotherapy followed by conformal
teleradiotherapy and patients receiving concurrent
chemotherapy and conformal teleradiothepay (details are
provided in the treatment protocol).
Tr e a t m e n t  p r o t o c o l
1. On qualification the following procedures were performed:
detailed case history, detailed physical examination, measu-
rements of body weight, Karnofsky status, bronchoscopy
followed by microscopic analysis of the cancer specimen,
spirometry, blood gas analysis, PA and lateral chest X-ray,
Computerised Tomography (CT) of the chest and ultrasono-
graphy and CT of the abdomen; CT of the brain, ECG,
coagulology, blood cell count, biochemical analyses hepa-
tic/renal function (transaminases, GGTP, bilirubin, creatinin
and creatinin clearance, ureal nitrogen, glucose and LDH),
serum protein with electrophoresis and the acid-base balance.
2. The inclusion criteria were:
– microscopically confirmed NSCLC not qualifying for
surgical treatment,
– age below 70 years,
– grade of malignancy III°A (N2 feature) and III°B acc. to
TNM (UICC 1997), without pleural effusion,
– Karnofsky status 70 points or over,
– decrease in body weight not exceeding 5% of calculated
body mass,
– hemoglobin level >11 g/d; WBC >4000/mm3; platelet
count >150 000 mm3,
– no respiratory insufficiency: spirometry and blood gas
analysis values as for radical radiotherapy (see [25]),
– adequate hepatic and renal function (in biochemical
analysis),
– no circulatory insufficiency (on clinical examination and in
ECG),
– no previous history of malignancy,
– no previous causative treatment.
3. Patients who fulfilled the inclusion criteria were randomly
assigned to one of the two groups (acc. to randomization
tables):
a) patients treated with induction chemotherapy followed
by external beam irradiation,
b) patients treated concurrently with chemotherapy and
external beam irradiation.
Conformal teleradiotherapy was applied in both groups, as
was the cisplatin-navelbine chemotherapy regimen.. The
difference between the two treatment protocols lay in fact
only in the sequence of chemotherapy and radiotherapy
administration.
4. Conformal teleradiotherapy was administered with the aid of
a CT device (General Electric) used only for the purpose of
treatment planning and a Varian therapeutic line. All basic
conditions of conformal radiotherapy were maintained i.e.
CT scanning for topographic data concerning the tumour
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W n i o s k i.  SkutecznoÊç sekwencyjnej i równoczesnej chemio- teleradioterapii chorych na miejscowo zaawansowanego,
nieoperacyjnego NKRP jest zbli˝ona, natomiast toksycznoÊç tej drugiej, znamiennie wy˝sza.
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and the critical organs, image transfer from the CT device to
the 3D treatment planning system, 3D reconstruction of the
target volume and of the organs at risk, virtual simulation
of the distribution of irradiation, 3D calculation of dose
distribution with presentation, treatment planning and
administration with the aid of a multileaf collimator (MLC),
individual shields, dose-volume histograms, apparatus for
patient positioning and immobilization in order to ascertain
the identical conditions of irradiation, in vivo dosimetry.
Irradiation was performed using conventional fractioning
(5 times a week, 1 fraction of 1.8 Gy per day). We ad-
ministered a dose of 50.4 Gy in 28 fractions to the primary
tumour site and the mediastinum (first stage of treatment)
and, additionally, 19.8 Gy in 11 fractions to the primary tumor
site and the macroscopically metastatic lymph nodes (i.e.
lymph nodes of 2 cm or more in diameter) [GTV – gross
tumor volume] (second stage of treatment). Altogether the
GTV received a dose of 70.2 y in 39 fractions.
During the first stage of treatment we irradiated the primary
tumour with a 2 cm margin and the mediastinum from the
sternal incision to 6 cm below the bifurcation of the trachea
(in case of tumours located in the superior or middle lobe) or
to the level of the diaphragm (in case of tumours located in
the inferior lobe). During the second stage of treatment the
tumour and the macroscopically metastatic lymph nodes
were irradiated with a 1 cm margin (to allow for respiratory
movement). The target volume did not exceed 500 cm3. In
patients in whom we observed regression after induction
chemotherapy the target volume was identical with that
calculated at the onset of treatment.
5. The detailed outline of treatment was as follows:
Group A (induction chemotherapy followed by teleradio-
therapy – sequential treatment) – 2 series of induction
chemotherapy (cisplatin 100 mg/m2 on day 1; navelbine
20 mg/m2 on day 1 and 8; a 28 day gap between courses).
Conformal radiotherapy began on day 8 of the second course.
Group B (concurrent chemotherapy and teleradiotherapy –
concurrent treatment) – cisplatin 100 mg/m2 administered
on day 1 and 36 of irradiation, navelbine 20 mg/m2 on day 1,
8, 36 and 43 of irradiation.
Supportive treatment was administered according to
generally accepted indications (anti-emetics, growth fractors,
hematopoesis stimulating drugs, antibiotics etc).
6. The first two follow up examinations were performed in the
6th and 12th week after the completion of treatment, the
following – every 3 months. The follow-up examinations
included physical examination, body weight, Karnofsky
performance status, blood cell count, hepatic and renal
function (biochemistry); chest X-ray (PA and lateral) and
chest CT was performed every 3 months during the first year
after treatment, and then every 6 months. Other exami-
nations were performed only when recurrence or disse-
mination were suspected.
7. The degree of regression was evaluated according to chest
imaging in accordance with the WHO criteria of response
to chemotherapy [26] and the RTOG/EORTC criteria of
response to radiotherapy [27].
8. The criterion appointed for the evaluation of treatment
results was 2-year survival without symptoms of cancer
(disease-free survival, DFS) calculating from the onset of
treatment. All patients were followed-up for 12 months,
unless death occurred. Mean duration of follow-up was
29 months. The probability of survival was calculated with
the Kaplan-Meier method [28]. In order to evaluate the
significance of the observed differences we used the log-rank
test acc. to Peto [29]. Statistical significance level was set at p-
value ≤0.05. In order to assess the impact of the assorted
factors on patient survival we applied Cox’s model of
proportional hazard [30].
Results
Between January 1st 2001 and December 31st 2004 we
had enrolled and observed 173 patients in the course of
the described trial, all with locoregionally advanced
nonresactable NSCLC. Sequential chemo-teleradio-
therapy was administered to 89 patients (group A) and
concurrent treatment – to 84 patients (group B).
Patient characteristics and microscopic/clinical data
of both the groups have been presented in Table I.
Table I. Patient characteristics and microscopic/clinical data
of patients treated with sequential (group A) 
and concurrent (group B) chemo-radiotherapy
Patient characteristics & Group A Group B
microscopic + clinical data No. of pts. % No. of pts. %
Age:
≤58 37 41.6 35 41.7
>58 52 58.4 49 58.3
Gender:
m 64 71.9 60 71.4
f 25 28.1 24 28.6
Microscopic tumour type:
Ca. planoepitheliale 61 68.5 56 66.7
Ca. glandulare 28 31.5 27 32.1
Ca. gigantocellulare – – 1 1.2
Karnofsky performance status:
70-80 75 84.3 71 84.5
90 14 15.7 13 15.5
Malignancy advancement:
IIIA 29 32.6 28 33.3
IIIB 60 67.4 56 66.7
Total 89 100.0 84 100.0
Data from Table I shows that the two patient groups
did not differ as to their characteristics.
The course of treatment has been presented in
Table II.
Complete combined modality treatment had been
administered to 86/89 patients (96.7%) from group A
and 63/84 (75%) of patients from group B. This difference
achieves extreme statistical significance (log-rank test
p<0.01). In all patients from both the groups we observed
inflammation of the oesophageal mucosa (grade 1 or 2),
moderate nausea and vomiting and myelosuppression of
a different degree. In 6.8% of patients undergoing
sequential treatment and 14.3% of patients undergoing
concurrent treatment the above-mentioned complications
enforced breaks in irradiation, lasting some 8-10 days,
after which treatment was resumed and completed.
In the sequential treatment group two patients died
due to treatment complications in the form of acute
inflammation of pulmonary tissue or sepsis in the course
of neutropoenia. In 1 patient treatment was discontinued
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due to the diagnosis of metastases to the central nervous
system in the course of teleradiotherapy.
In the concurrent treatment group in 2 cases
treatment was discontinued due to cancer progression
(metastases to the bones, the liver and the brain), 1
patient withdrew consent in the course of the trial, in 18
cases (21.4%) treatment was discontinued due to its
excessive toxicity taking the form of severe (grade 3 and 4)
inflammation of the oesophageal mucosa in 7 cases,
severe inflammation of the pulmonary tissue with
respiratory insufficiency in 5 cases, leucopoenia and
thrombocytopoenia in 4 cases and significant alterations
in hepatic and renal function in 2 cases. Two patients
died due to these complications, one in the course of
acute pneumonia and the other due to the generalized
sepsis.
The degree of tumour regression was evaluated
6 weeks after treatment completion and has been
presented in Table III.
Table III. The degree of tumour regression 6 weeks 
after treatment completion
Degree of radiological tumour Group A Group B
regression No. of pts. % No. of pts. %
Complete regression 12 13.5 11 13.1
Partial regression 48 53.9 46 54.8
Regression <50% or lack 
of regression 18 20.2 17 20.2
Progression 11 12.4 10 11.9
Total 89 100.0 84 100.0
As may be derived from Table III no statistically
significant differences have been found between the two
groups regarding early tumour regression – 6 weeks after
treatment completion. Complete or partial radiological
regression (>50%) was observed in 67.4% of patients
from group A and 67.9% of patients from group B.
As may be derived from Table IV no statistically
significant differences have been found between the two
groups regarding the treatment results. In the sequential
treatment group 2-year overall survival was 25.8%, with
11.2% of disease-free survival; in the concurrent
treatment group these values were 25% and 11.9%
respectively. Table V presents the treatment results
observed in patients who had completed the treatment,
i.e. 86 patients from group A and 63 patients from
group B.
When analyzing the contents of Table V one may
notice that if a patient had completed treatment accord-
ing to the concurrent treatment protocol he or she had
a higher (though not statistically significant) chance of
surviving 2 years, both as overall survival and as disease-
free survival (33.3% vs. 26.7% and 15.9 vs. 11.6%), as
compared to patients treated according to the sequential
protocol. However, in our material, this effect is nullified
by the higher toxicity observed in the concurrent
treatment group.
Table V. Survival of patients treated with sequential (group A) 
and concurrent (group B) chemo-radiotherapy 
who had completed treatment
2-year survival Group A [86 pts.] Group B [63 pts.]
No. of pts. % No. of pts. %
overall 23 26.7 21 33.3
disease-free 10 11.6 10 15.9
We did not observe differences in the treatment
results regarding patient gender, age, the microscopic
form of the tumour and Karnofsky status within the 70-90
point range. The correlation between 2-year survival and
the advancement of the malignancy is presented in
Table VI.
Both in univariate and multivariate analysis the only
prognostic factor (which as such was noticeable in both
groups) was the advancement of the malignancy. Patients
in stage III°A had a statistically significantly higher chance
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Table II. The course of treatment of patients treated with sequential (group A) and concurrent (group B) chemo-radiotherapy
Treatment course Group A Group B
No. of pts. % No. of pts. %
Complete treatment administered as scheduled over the intended time 80 89.9 51 60.7
Complete treatment administered over an elongated treatment time 6 6.8 12 14.3
Treatment not completed due to:
excessive toxicity 2 2.2 18 21.4
cancer progression 1 1.1 2 2.4
consent withdrawal – – 1 1.2
Total 89 100.0 84 100.0
Table IV. Prognosed survival of patients treated with sequential
(group A) and concurrent (group B) chemo-radiotherapy
2-year survival Group A [89 pts.] Group B [84 pts.]
No. of pts. % No. of pts. %
overall 23 25.8 21 25.0
disease-free 10 11.2 10 11.9
of achieving 2-year overall survival as compared to
patients with stage III°B tumours (log-rank test, p<0.02).
Discussion
There is no doubt as to the fact that in case of patients
with locoregionally advanced, nonresactable NSCLC the
treatment of choice is, at present, combined radio- and
chemotherapy. It allows to achieve slightly better results
than radiotherapy applied as a sole modality [1, 5, 8, 10,
20, 31-36].
The study, which we present here – a prospective
randomized trial – has provided us with data which
enables us to participate in the discussion concerning the
optimal method of combining chemotherapy and
teleradiotherapy in this particular group of patients.
173 patients with locoregionally advanced, nonresactable
NSCLC were enrolled into the study; they were randomly
assigned to receive either induction chemotherapy
followed by conformal teleradiotherapy (n=89; group A
– sequential treatment) or concurrent chemotherapy and
teleradiotherapy (n=84; group B – concurrent treatment).
Both chemotherapy (cisplatin and navelbine) and
teleradiotherapy (conformal) were identical in both
groups – the only differences arose from the sequence
according to which the two modalities were administered.
We observed statistically significantly higher toxicity
of concurrent treatment as compared to sequential
treatment. Due to this toxicity the treatment was not
completed in 21.4% of patients from the concurrent
group and in 2.2% of patients from the sequential group.
These results remain in accordance with literature data [1,
3, 5, 7, 8, 10, 28].
Acute inflammation of the oesophageal mucosa was
the reason for treatment discontinuation in 7/84 patients
(8.3%) treated according to the concurrent treatment
protocol; it was the most frequent complication in this
patient group. In none of the patients treated sequentially
was it necessary to discontinue treatment due to this
particular complication. Literature data, including the
results of three controlled clinical trials, confirms that
oesophageal mucositis is the main complication of
concurrent treatment [5, 10, 17, 37-40]. Curran et al.
report acute oesophagitis (3°) in 5% of patients treated
sequentially, as compared to 26% in the case of patients
treated according to the concurrent protocol [37], and, in
the next study, 4% and 21% respectively [38].
The remaining severe complications caused by
concurrent treatment, i.e. granulocytopoenia and throm-
bocytopoenia and acute inflammation of pulmonary tissue
are also reported by other authors [17, 41].
The results of treatment were found not to differ
between the two groups. Complete radiological regression
evaluated 6 weeks after treatment completion was ob-
served in 13.5% of patients treated sequentially and in
13.1% of patients treated concurrently. Partial regression
(>50%) was observed in 53.9% and 54.8% of patients,
respectively. Altogether the >50% regression index was
found to be 67.4% and 67.9%, respectively. In the study of
Furuse et al. the total regression ratio ranged between
66% and 84%, in the study of Winterhalder et al. it was
65% (CR-12%) and in the study of Vokes et al. – 66-69%
(CR-8-19%) [17, 39, 41].
The results of 2-year overall survival were also
similar: 25.8% in the sequential treatment group and
25% in the concurrent treatment group, as was the 2-
year disease-free survival – 11.2% and 11.9%, respectively.
These results are also similar to those reported in
literature, where 2-year survivals vary from 13% to 27%
[7, 33, 35, 41-46%].
Our results have not shown the concurrent treatment
regime to be superior to sequential treatment. Although,
when comparing the results achieved by patients who had
managed to complete the planned treatment concurrent
therapy did appear more effective (although this failed to
reach statistical significance), yet this gain was completely
overruled by the significantly higher treatment toxicity.
Literature reports maintain that concurrent treatment is
more effective than sequential treatment [1, 5, 7, 8, 10, 17,
37-41, 47, 48]. This also appears to be the conclusion of 4
controlled clinical trials [37, 39, 47, 48].
In the RTOG 94-10 study, in the course of which
611 patients had been randomized, mean survival in the
concurrent treatment group was 17 months, while in the
sequential treatment group it was only 14.6 months
(p=0.08) [37]. In a Japanese trial involving 320 patients
the response ratio was significantly higher in the con-
current treatment group, as compared to the sequential
treatment group (84% vs. 66%), as was the mean survival
(16.5 months vs. 13.3 months) (p=0.04) [39]. In both of
these studies treatment toxicity was greater in the
concurrent treatment group.
In our material, in both the patient groups the only
prognostic factor was the degree of disease advancement
– in patients with III°A tumours the chances of 2-year
survival were significantly higher than in patients with
III°B tumours. Careful patient qualification made it
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Table VI. Correlation between 2-year overall survival and the advancement of the malignancy
Advancement of malignancy Group A Group B
No. of pts. treated 2-year survival No. of pts. treated 2-year survival
No. of pts. % No. of pts. %
III°A 29 13 44.8 28 13 46.4
III°B 60 10 16.7 56 8 14.3
Total 89 23 25.8 84 21 25.0
impossible for the other prognostic factors, such as the
performance status, weight loss and gender etc. [1], to
render their impact.
In the recent years attempts have been made at
performing phase II trials aimed at increasing the efficacy
of combined chemotherapy and radiotherapy in patients
with advanced NSCLC. The evaluated modalities include:
– new drug combinations eg. carboplatin + paclitaxel,
cisplatin + paclitaxel, cisplatin + carboplatin, cisplatin
+ etoposide, cisplatin + gemcytabin etc [1, 3, 5, 8, 10,
17, 36, 46];
– combining sequential and concurrent treatment [1, 17,
49, 50];
– combining chemotherapy and radiotherapy using
unconventional methods of dose fractionation (hyper-
fractionation, accelerated hyperfractionation, irra-
diation with planned interval) [22, 24, 36, 46];
– combining induction treatment with concurrent
treatment with radiation dose escalation using 3D
planning [10].
Generally, a number of studies have failed to
improve the results of treatment [8, 17, 22, 24, 41, 49,
50], while some provide only minor improvement [17, 36,
46, 51, 52]; phase III trials are a necessity. At present it is
certain that only patients with a good performance status
and without significant weight loss may be qualified for
combined chemotherapy and radiotherapy, especially
administered concurrently [1, 5, 8]; sequential regimes
are safer [8, 31].
Conclusion
The efficacy of sequential and concurrent chemotherapy
and teleradiotherapy in patients with locoregionally
advanced nonresactable NSCLC is comparable, while the
toxicity of concurrent treatment is significantly higher.
Marian Reinfuss MD, Ph.D.
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